UR Code is a urine marker that “bar-codes” a subject’s urine and eliminates the need to supervise urine collection. In the form of a soft gel capsule, UR Code is the only patented test worldwide that can analytically detect sample substitution, dilution or adulteration, resulting in unparalleled accuracy and reliability. This superior level of accuracy eliminates up to 30% of the tests that are deliberately falsified in urine drug testing.
The agreement provides Elithea Sciences with a distinct competitive advantage to improve confirmation testing results to physicians and clinics in chronic pain management markets Florida and Texas. In addition, Elithea has the right of first refusal from Marker Test for six additional states: Georgia, Kentucky, Louisiana, Mississippi, Tennessee and West Virginia. The companies plan to commercialize the product before the end of the summer.
“We believe partnering with Elithea Sciences will be the first step in changing the culture of the drug testing industry in the United States,” said Marker Test Chief Executive Officer Kim Christensen. “Together, we have listened to important segments of the industry and recognize that eliminating the observed urine collection process is a major accomplishment in improving the overall integrity and quality of the urine sample, while returning dignity and respect to the sample donor. Elithea Sciences now has an exclusive tool to eliminate the false negative urine known as the ‘substituted sample.’”
“Marker Test’s break-through innovation in drug testing is the perfect complement to Elithea’s subscription recurring revenue-based business model and specialized focus on chronic pain management,” stated Mac Brown, Chief Executive Officer of Elithea Sciences. “Through this partnership with Marker Test, Elithea is offering an investment opportunity in the only solution in the urine drug testing market that virtually assures 100% accuracy and reliability in sample collection, resulting in dramatically-improved patient care.”
Representatives from Marker Test will be on-site during the 2015 American Association for Clinical Chemistry (AACC) Annual Meeting July 26–30 at the Georgia World Congress Center in Atlanta, Ga (booth 4918). A press conference to discuss the UR Code product, Marker Test’s partnership with Elithea Sciences and the company’s plans for further expansion in the U.S. is scheduled for Wednesday, July 29, at 11:00 a.m. ET. Interested parties may access the conference remotely by dialing (719) 457-6209 and entering passcode 243908.
About Marker Test DiagnosticsFounded in 2013, Marker Test Diagnostics is the producer of UR Code (TM), an innovative urine marker for the drug testing market. Marker Test Diagnostics has completed research studies in the field of addiction and sports, and has collaborated and published scientific papers with the Olympic Doping Laboratory at the University of California Los Angeles, and the Columbia University / New York State Psychiatric Institute.
For more information about Marker Test Diagnostics, visit www.markertest.com.
About Elithea SciencesElithea Sciences is a leading provider of drug confirmation testing, toxicology and analytical services. We offer specialized range of customizable solutions for accurate, reliable and cost effective testing with a specific focus on prescription medication management, illicit substance identification and performance enhancing drug detection using only the most advanced LC-MS/MS technology available today. Elithea provides a safe, effective and discreet solution for drug testing analysis that virtually assures 100% accuracy and reliability in obtained sample integrity. For more information about Elithea Sciences, visit www.elithea.care.
###
RSS